Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients

被引：46

作者：

Gobbini, Elisa ^{[1
,2
]}

Toffart, Anne Claire ^{[1
]}

Perol, Maurice ^{[3
]}

Assie, Jean-Baptiste ^{[4
]}

Duruisseaux, Michael ^{[5
,6
,7
]}

Coupez, Dahna ^{[8
]}

Dubos, Catherine ^{[9
]}

Westeel, Virginie ^{[10
]}

Delaunay, Myriam ^{[11
]}

Guisier, Florian ^{[12
]}

Veillon, Remi ^{[13
]}

Gounant, Valerie ^{[14
]}

Leprieur, Etienne Giroux ^{[15
]}

Vanel, Francois-Roger ^{[16
]}

Chaabane, Nouha ^{[17
]}

Dansin, Eric ^{[18
]}

Babey, Helene ^{[19
]}

Decroisette, Chantal ^{[20
]}

Barlesi, Fabrice ^{[21
]}

Daniel, Catherine ^{[22
]}

Fournel, Pierre ^{[23
]}

Mezquita, Laura ^{[24
]}

Oulkhouir, Youssef ^{[25
]}

Canellas, Anthony ^{[26
,27
]}

Duchemann, Boris ^{[28
]}

Molinier, Olivier ^{[29
]}

Alcazer, Vincent ^{[2
]}

Moro-Sibilot, Denis ^{[1
]}

Levra, Matteo Giaj ^{[1
]}

机构：

[1] CHU Grenoble Alpes, Thorac Oncol Unit SHUPP, Grenoble, France

[2] Ctr Leon Berard, Canc Res Ctr Lyon, Lyon, France

[3] Leon Berard Canc Ctr, Dept Med Oncol, Lyon, France

[4] CHU Creteil, Thorac Oncol Unit, Paris, France

[5] Hosp Civils Lyon, Unite Rech Commune Oncol Thorac URCOT, Canc Inst, Lyon, France

[6] Canc Res Ctr Lyon, Anticanc Antibodies Lab, Inserm 1052, CNRS 5286, Lyon, France

[7] Univ Claude Bernard Lyon 1, Univ Lyon, Lyon, France

[8] CHU Nantes, Thorac Oncol Unit, Nantes, France

[9] Ctr Francois Baclesse, Thorac Oncol Unit, Caen, France

[10] CH Besancon, Thorac Oncol Unit, Besancon, France

[11] CHU Toulouse, Pulmonol Dept, Toulouse, France

[12] CHU Rouen, Pneurnol Thorac Oncol & Resp Intens Care Unit, Rouen, France

[13] CHU Bordeaux, Resp Dis Dept, F-33000 Bordeaux, France

[14] Ctr Bichat, Thorac Oncol Dept, CIC INSERM 1425, Paris, France

[15] Hop Ambroise Pare, AP HP, Dept Resp Dis & Thorac Oncol, Paris, France

[16] CHU Strasbourg, Thorac Oncol Unit, Strasbourg, France

[17] Cochin Hosp, AP HP, Pulmonol Serv, Paris Ctr Univ Hosp, Paris, France

[18] Ctr Oscar Lambret, Thorac Oncol Unit, Lille, France

[19] CHRU Brest, Thorac Oncol Unit, Brest, France

[20] CH Annecy Genevois, Pulmonol & Thorac Oncol Unit, Annecy, France

[21] Aix Marseille Univ, AP HM, CRCM, CNRS,INSERM, Marseille, France

[22] Inst Curie, Thorac Oncol Unit, Paris, France

[23] Inst Cancerol Loire, Med Oncol Dept, Saint, France

[24] Gustave Roussy, Thorac Grp, Dept Med Oncol, Villejuif, France

[25] CHU Caen, Pulmonol & Thorac Oncol Unit, Caen, France

[26] Hop Tenon, AP HP, Pulmonol Unit, Paris, France

[27] GRC 04 Theranoscan Sorbonne Univ, Paris, France

[28] Ctr Bobigny, Thorac Oncol Unit, Paris, France

[29] CH Le Mans, Thorac Oncol Unit, Le Mans, France

来源：

CLINICAL LUNG CANCER | 2020年 / 21卷 / 05期

关键词：

Immune checkpoint inhibitors; NSCLC; Re-challenge; Selection criteria; PRETREATED ADVANCED MELANOMA; OPEN-LABEL; IPILIMUMAB RETREATMENT; CHOICE CHEMOTHERAPY; NIVOLUMAB; DOCETAXEL; ATEZOLIZUMAB; MULTICENTER; SURVIVAL; SAFETY;

D O I：

10.1016/j.cllc.2020.04.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score. Background: Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national study explored the efficacy of anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) rechallenge in advanced NSCLC patients, looking for potential clinical features associated with greater outcomes. Patients and Methods: We retrospectively collected data from 144 advanced NSCLC patients whose disease was rechallenged with ICP is after >= 12 weeks of discontinuation. The progression-free survival (PFS) and overall survival (OS) were calculated from first or second ICPi initiation to disease progression (PFS1 and PFSR, respectively), death, or last follow-up (OS1, OSR), respectively. Results: The median (interquartile range) age was 63 (58-70) years. Most patients were male (67%) and smokers (87%). Most had adenocarcinomas (62%) and/or stage IV disease at diagnosis (66%). The best response at rechallenge was not associated with that under the first ICPi (P = 1.10(-1)). The median (95% confidence interval) PFS1 and PFSR were 13 (10-16.5) and 4.4 (3-6.5) months, respectively. The median (95% confidence interval) OS1 and OSR were 3.3 (2.9-3.9) and 1.5 (1.0-2.1) years, respectively. Longer PFSR and OSR were found in patients discontinuing first ICPi because of toxicity or clinical decision, those not receiving systemic treatment between the two ICPis, and those with good Eastern Cooperative Oncology Group performance status at rechallenge. Only performance status proved to affect outcomes at multivariate analysis. Conclusion: Patients discontinuing first ICPi because of toxicity or clinical decision, those able to maintain a treatment-free period, and those with good performance status may be potential candidates for rechallenge. (C) 2020 Elsevier Inc. All rights reserved.

引用

页码：E497 / E510

页数：14

共 25 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3] Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy [J].

Chiarion-Sileni, V. ;

Pigozzo, J. ;

Ascierto, P. A. ;

Simeone, E. ;

Maio, M. ;

Calabro, L. ;

Marchetti, P. ;

De Galitiis, F. ;

Testori, A. ;

Ferrucci, P. F. ;

Queirolo, P. ;

Spagnolo, F. ;

Quaglino, P. ;

Schianca, F. Carnevale ;

Mandala, M. ;

Di Guardo, L. ;

Del Vecchio, M. .

BRITISH JOURNAL OF CANCER, 2014, 110 (07) :1721-1726

[4] Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer [J].

Costantini, Adrien ;

Corny, Jennifer ;

Fallet, Vincent ;

Renet, Sophie ;

Friard, Sylvie ;

Chouaid, Christos ;

Duchemann, Boris ;

Giroux-Leprieur, Etienne ;

Taillade, Laurent ;

Doucet, Ludovic ;

Nguenang, Marina ;

Jouveshomme, Stephane ;

Wislez, Marie ;

Tredaniel, Jean ;

Cadranel, Jacques .

ERJ OPEN RESEARCH, 2018, 4 (02)

[5]

Dummer R, 2016, ANN ONCOL, V27, P379, DOI DOI 10.1093/ANNONC/MDV617

[6] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[7] Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study [J].

Garon, Edward B. ;

Hellmann, Matthew D. ;

Rizvi, Naiyer A. ;

Carcereny, Enric ;

Leighl, Natasha B. ;

Ahn, Myung-Ju ;

Eder, Joseph Paul ;

Balmanoukian, Ani S. ;

Aggarwal, Charu ;

Horn, Leora ;

Patnaik, Amita ;

Gubens, Matthew ;

Ramalingam, Suresh S. ;

Felip, Enriqueta ;

Goldman, Jonathan W. ;

Scalzo, Cathie ;

Jensen, Erin ;

Kush, Debra A. ;

Hui, Rina .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) :2518-+

[8] Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study [J].

Gettinger, Scott ;

Horn, Leora ;

Jackman, David ;

Spigel, David ;

Antonia, Scott ;

Hellmann, Matthew ;

Powderly, John ;

Heist, Rebecca ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Geese, William J. ;

Yoon, Dennis ;

Li, Ang ;

Brahmer, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1675-+

[9] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].

Goldstraw, Peter ;

Crowley, John ;

Chansky, Kari ;

Giroux, Dorothy J. ;

Groome, Patti A. ;

Rami-Porta, Ramon ;

Postmus, Pieter E. ;

Rusch, Valerie ;

Sobin, Leslie .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714

[10] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

← 1 2 3 →